In this episode of Know What You Are Investing, we unpack AbbVie’s stellar second quarter of 2025. With total revenues surpassing $15.4B and strong performance in immunology, neuroscience, and oncology, AbbVie is showing investors a powerful vision beyond HUMIRA.

🔥 What’s Inside

🔹 Skyrizi and Rinvoq set to exceed $25B in 2025 combined sales

🔹 Neuroscience growth led by Vraylar, QULIPTA, and VYALEV

🔹 Oncology resilience and aesthetic segment headwinds

🔹 30+ business development deals including obesity, CAR-T, ADCs

🔹 Strategic investments in U.S. manufacturing & next-gen therapies

🔹 IRA updates and tariff outlook

🔹 Analyst Q&A highlights and Q3–Q4 guidance

🎯 Whether you’re an investor, analyst, or healthcare innovation enthusiast — this is your full breakdown of how AbbVie is engineering its next decade of growth.

🎙️ Know What You Are Investing Podcast

🔍 What they do

🚀 How they grow

📊 Why it matters